A Comparative Review of Vitamin E and Associated Equine Disorders

Vitamin E is a primary chain‐breaking antioxidant that prevents cyclic propagation of lipid peroxidation. Across species, vitamin E is essential for normal neuromuscular function by acting as a potent antioxidant, as well as by modulating the expression of certain genes, inhibiting platelet aggregation and stabilizing plasma membranes. This review focuses on vitamin E structure, absorption, metabolism, current equine dietary recommendations, the interplay between antioxidants and exercise, a discussion of the necessity of vitamin E supplementation in the horse above the Nutritional Research Council (NRC) 2007 requirements, and a review of equine diseases that are associated with a vitamin E deficiency. Particular emphasis is placed on the proteins involved in vitamin E absorption, transport, and metabolism as potential candidates for vitamin E‐associated diseases across species.     

蛋鸡淋巴白血病的诊断

2011年某蛋鸡场部分病鸡内脏发生增生性肿瘤性疾病,经流行病学调查、临床诊断及实验室检测,确诊为鸡J亚型淋巴白血病。文章就该病例的诊断过程做了详细阐述,并对禽常见传染性肿瘤病的鉴别、白血病的预防和控制进行了归纳总结。     

凉山草坪病虫害及其防治途径初探

本文在调查研究凉山草坪病虫害的基础上,对草坪的病虫害防治进行了初步探讨和研究,并提出了解决途径.     

锡林郭勒盟草原莱姆病疫源地调查

本项研究于2000年5月—2001年5月从内蒙古锡林郭勒盟地区，不同草原景现带牛、羊体表和草地采集草原血蝉1800只，用直接荧光抗体法检查蜱带菌情况，带菌率为7.5%(6/80)。晴视野显微镜检查蜱带菌情况，带菌率为2%（2/100）；用间接荧光法进行血清流行病学调查，结果证实，调查点的牛和野鼠均存在莱姆病螺旋体感染，其感染率分别为10%和20%，都高于当地人群平均感染率（7.09%)，上述研究证实内蒙古锡林郭勒盟地区人畜及野生动物均有莱姆病螺旋体感染。     

甘肃省肃南县草地治蝗灭鼠工作经验

总结了肃南县１９５５年以来草原治蝗灭鼠为单一人工药物防治发展到生物新技术与新药物相结合的综合治理经验,提出了今后科技力量,开展多渠道,多学科,多部门协作防治的发展方向。     

试论草坪主动除草

根据1999－202年在50多个高尔夫球场草坪防除杂草的实践，基于土壤中杂草种子库、杂草与草坪竞争的生态学原理，提出了草坪主动除草的理论。包含控杂草于危害前，树草坪竞争优势，治理杂草种子库，预防潜在的杂草问题。阐述了如何取得杂草防除、保持杂草防除的主动权以及如何制定主动防除草坪杂草的方案。     

水利工程施工成本的控制

施工成本是工程成本控制的主要内容,水利水电工程施工成本有效控制是工程施工管理的核心,如何实现水利水电工程施工成本有效控制显的尤为重要。只要科学地组织和规划,采取适当的控制标准,严格的按规章实施,工程施工成本的控制就会取得良好的效果。     

A prospective,randomized, double-blind,placebo-controlled multisite,parallel-group field study in dogs with osteoarthritis conducted in the United States of America evaluating bedinvetmab,a canine anti-nerve growth factor monoclonal antibody

ObjectiveBedinvetmab, a fully canine anti-nerve growth factor monoclonal antibody, was evaluated in dogs for control of osteoarthritis-related pain in a study conducted to support registration in the USA.Study designRandomized, double-blind, placebo-controlled, multicenter, parallel-group study.AnimalsGeneral practice client-owned dogs with osteoarthritis (n = 272).MethodsDogs were block randomized 1:1 to placebo (saline, n = 137) or bedinvetmab (n = 135; 0.5–1.0 mg kg^–1) administered subcutaneously, once monthly. The primary end point, day 28 Canine Brief Pain Inventory (CBPI) treatment success (TS), required pain severity score (PSS; 0–10) decrease ≥1 and pain interference score (PIS; 0–10) decrease ≥ 2. CBPI TS rates [and number needed to treat (NNT)], change in scores [and standardized effect size (ES)], change in quality of life (QoL) and bedinvetmab half-life were calculated.ResultsSignificant (p < 0.05) improvement with bedinvetmab over placebo occurred (days 28, 42, 56, 84) for CBPI TS. Of cases evaluable for day 28 CBPI TS (placebo, n = 131; bedinvetmab, n = 128), success rates were 36.6% and 47.4%, respectively (p = 0.0410) (NNT, 9.3; PSS and PIS ES, 0.3). CBPI TS increased after the second dose in both groups, plateaued for bedinvetmab at day 42 and decreased for placebo beginning day 84. Day 84 NNT (4.3), PSS (0.4) and PIS (0.5) showed continued improvement with monthly dosing. After the first dose, mean (± standard deviation) bedinvetmab half-life was 19.1 (8.3) days. Adverse events were similar between groups and not considered treatment-related. There was a significant effect of bedinvetmab versus placebo on all CBPI components (PIS, PSS, QoL).Conclusions and clinical relevanceThese results corroborated those previously reported and provide further support of safety and effectiveness of bedinvetmab (0.5–1.0 mg kg^–1) administered subcutaneously at monthly intervals to dogs for control of osteoarthritis-related pain.